MX352074B - Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. - Google Patents

Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Info

Publication number
MX352074B
MX352074B MX2014003660A MX2014003660A MX352074B MX 352074 B MX352074 B MX 352074B MX 2014003660 A MX2014003660 A MX 2014003660A MX 2014003660 A MX2014003660 A MX 2014003660A MX 352074 B MX352074 B MX 352074B
Authority
MX
Mexico
Prior art keywords
cetp
benzylaminomethyl
aminopyrazolo
atherosclerosis
treatment
Prior art date
Application number
MX2014003660A
Other languages
English (en)
Other versions
MX2014003660A (es
Inventor
Boruah Anima
Alikunju Shanavas
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of MX2014003660A publication Critical patent/MX2014003660A/es
Publication of MX352074B publication Critical patent/MX352074B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente solicitud se refiere a una serie de pira-zolopiridin-6-aminas sustituidas que tienen la fórmula general (I), incluyendo sus estereoisómeros y/o sus sales farmacéuticamente aceptables. En donde R, R1, R2, Ra, Raa, Rb y n son como se definen en la presente. La presente invención además se refiere a composiciones farmacéuticas que comprenden compuestos de la fórmula (I) . Los compuestos de esta solicitud son útiles como inhibidores CETP para incrementar el colesterol HDL y disminuir el colesterol LDL en un paciente.
MX2014003660A 2011-09-27 2012-09-27 Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis. MX352074B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN3337CH2011 2011-09-27
US201161558262P 2011-11-10 2011-11-10
PCT/IB2012/002435 WO2013046045A1 (en) 2011-09-27 2012-09-27 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis

Publications (2)

Publication Number Publication Date
MX2014003660A MX2014003660A (es) 2014-10-17
MX352074B true MX352074B (es) 2017-11-08

Family

ID=47994351

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014003660A MX352074B (es) 2011-09-27 2012-09-27 Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.

Country Status (11)

Country Link
US (1) US9000007B2 (es)
EP (1) EP2760864B1 (es)
JP (1) JP6140168B2 (es)
KR (1) KR101803866B1 (es)
CN (1) CN103958511A (es)
AU (1) AU2012313971B2 (es)
CA (1) CA2850022C (es)
HK (1) HK1197238A1 (es)
IN (1) IN2014CN02290A (es)
MX (1) MX352074B (es)
WO (1) WO2013046045A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014017569A1 (ja) * 2012-07-26 2014-01-30 興和株式会社 血中ｌｄｌを低下させるための医薬
JP2015054838A (ja) * 2013-09-12 2015-03-23 興和株式会社 血中ｌｄｌコレステロールを低下させる医薬
NO3081566T3 (es) * 2013-12-13 2018-08-04
CN109956940A (zh) * 2019-05-14 2019-07-02 上海贤鼎生物科技有限公司 一种帕博昔布中间体氰基化反应制备杂芳基氰化物的方法

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2965643A (en) 1960-12-20 Derivatives of pyrazolo
US2858309A (en) 1956-05-07 1958-10-28 Ciba Pharm Prod Inc New aminobenzene sulfonamide
US3546295A (en) 1968-08-01 1970-12-08 Exxon Research Engineering Co N-cycloalkyl anilines
DE3143016A1 (de) 1980-10-29 1982-05-27 Nippon Kayaku K.K., Tokyo 5,6,7,8-tetrahydro-1,6-naphthyridinderivate und verfahren zu ihrer herstellung
JPH01104052A (ja) 1987-06-12 1989-04-21 Yoshitomi Pharmaceut Ind Ltd ピリジン誘導体
ES2058288T3 (es) 1987-07-08 1994-11-01 American Home Prod Composiciones de ibuprofen secadas por atomizacion.
US5474989A (en) 1988-11-11 1995-12-12 Kurita Water Industries, Ltd. Drug composition
US5086073A (en) 1989-06-02 1992-02-04 John Wyeth & Brother Limited Composition for treating depression with aralkyl amines
US5260331A (en) 1989-01-02 1993-11-09 John Wyeth & Brother Limited Composition for treating depression with (S- or O-heteroaryl)alkyl amines
US5422355A (en) 1989-06-02 1995-06-06 John Wyeth & Brother, Limited Composition for treating depression with (N-heteroaryl)alkylamines
EP0580860B2 (en) 1991-04-16 2004-12-15 Nippon Shinyaku Company, Limited Method of manufacturing solid dispersion
US5348953A (en) 1991-06-25 1994-09-20 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
WO1993000332A1 (en) 1991-06-25 1993-01-07 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
TW225469B (es) 1991-11-12 1994-06-21 Nissan Kagakl Kogyo
FR2686339B1 (fr) 1992-01-22 1994-03-11 Adir Cie Nouveaux amides et sulfonamides naphtaleniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
US5482967A (en) 1992-09-04 1996-01-09 Takeda Chemical Industries, Ltd. Condensed heterocyclic compounds, their production and use
EP0585500A1 (en) 1992-09-04 1994-03-09 Merrell Dow Pharmaceuticals Inc. Diaryl piperazineacetamides as antimuscarinic agents
MY131441A (en) 1992-12-29 2007-08-30 American Cyanamid Co Amidrazones and their use as insecticidal and acaricidal agents
RU2130017C1 (ru) 1993-08-12 1999-05-10 Астра Актиенболаг Производные амидина, способ их получения и лекарственное средство на их основе, обладающее свойством ингибировать активность синтетазы оксида азота (у)
US5491152A (en) 1994-03-23 1996-02-13 The Du Pont Merck Pharmaceutical Company Derivatives of cyclic ethers and sulfides for the treatment of atherosclerosis
JPH07285962A (ja) 1994-04-20 1995-10-31 Nissan Chem Ind Ltd ピリジンカルボン酸アミド誘導体
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
JPH0892224A (ja) 1994-09-16 1996-04-09 Kumiai Chem Ind Co Ltd ３，５−置換フェニルトリアゾール誘導体および殺虫、殺ダニ剤
JPH0892225A (ja) 1994-09-29 1996-04-09 Nissan Chem Ind Ltd トリアゾールグリコール酸アミド誘導体
US5856347A (en) 1994-11-29 1999-01-05 Hisamitsu Pharmaceutical Co., Inc. Antibacterial preparation or bactericide comprising 2-aminothiazole derivative and/or salt thereof
GB9511220D0 (en) 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6730679B1 (en) 1996-03-22 2004-05-04 Smithkline Beecham Corporation Pharmaceutical formulations
DE19615262A1 (de) 1996-04-18 1997-10-23 Bayer Ag Heteroverknüpfte Phenylglycinolamide
NZ330739A (en) 1996-05-20 1999-06-29 Janssen Pharmaceutica Nv Particulate solid dispersion of itraconazole and a water soluble polymer
AR008789A1 (es) 1996-07-31 2000-02-23 Bayer Corp Piridinas y bifenilos substituidos
DE19636150A1 (de) 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
TW523506B (en) 1996-12-18 2003-03-11 Ono Pharmaceutical Co Sulfonamide or carbamide derivatives and drugs containing the same as active ingredients
US6008362A (en) 1997-06-16 1999-12-28 Commons; Thomas Joseph Elevation of HDL cholesterol by 2-(-4-chlorol-1-aryl-butylidene)-hydrazinecarbothioamides
US5977170A (en) 1997-06-16 1999-11-02 American Home Products Corporation Elevation of HDL cholesterol by 4-[(aminothioxomethyl)hydrazono]-4-arylbutyl carbamates
WO1998057928A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-(4-chloro -1-aryl-butylidene) -hydrazinecarbothioamides
WO1998057925A1 (en) 1997-06-16 1998-12-23 American Home Products Corporation Elevation of hdl cholesterol by 2-[(aminothioxomethyl)-hydrazono]-2-arylethyl carbamates
AU7589498A (en) 1997-06-16 1999-01-04 American Home Products Corporation Elevation of hdl cholesterol by 4-{(aminothioxomethyl)hydrazono}-4-arylbutyl carbamates
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
UA67754C2 (uk) 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
JPH11209366A (ja) 1998-01-23 1999-08-03 Nissan Chem Ind Ltd クロマン誘導体及び心不全治療薬
DE19814838C2 (de) 1998-04-02 2001-01-18 Asta Medica Ag Indolyl-3-glyoxylsäure-Derivate mit Antitumorwirkung
US6121271A (en) 1998-05-12 2000-09-19 American Home Products Corporation Naphtho[2,3-B]heteroar-4-yl derivatives
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6350786B1 (en) 1998-09-22 2002-02-26 Hoffmann-La Roche Inc. Stable complexes of poorly soluble compounds in ionic polymers
DE19845202A1 (de) 1998-10-01 2000-04-06 Wella Ag Haarwuchsmittel
CN1236813C (zh) 1998-12-11 2006-01-18 药品处理公司 水难溶性药物的自乳化组合物
ES2306646T3 (es) 1999-02-09 2008-11-16 Pfizer Products Inc. Composiciones de farmacos basicos con biodisponibilidad incrementada.
JP4070957B2 (ja) 1999-02-24 2008-04-02 エフ．ホフマン−ラ ロシュ アーゲー フェニルおよびピリジニル誘導体
AR024423A1 (es) 1999-06-23 2002-10-02 Syngenta Participations Ag PROCESO PARA LA PREPARACIoN DE TIAMETOXAM.
DE19930075A1 (de) 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
US6458852B1 (en) 1999-09-23 2002-10-01 G.D. Searle & Co. Use of substituted N, N-bis-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
TWI269654B (en) 1999-09-28 2007-01-01 Baxter Healthcare Sa N-substituted indole-3-glyoxylamide compounds having anti-tumor action
IL139941A0 (en) 1999-12-02 2002-02-10 Pfizer Prod Inc Use of prostaglandin agonists to treat erectile dysfunction or impotence
WO2001045674A1 (en) 1999-12-20 2001-06-28 Cocensys, Inc. Process for producing nanometer particles by fluid bed spray-drying
DE19962300A1 (de) 1999-12-23 2001-06-28 Asta Medica Ag Substituierte N-Benzyl-Indol-3-yl-glyoxylsäure-Derivate mit Antitumorwirkung
US6306911B1 (en) 2000-02-07 2001-10-23 Ortho-Mcneil Pharmaceutical, Inc. Substituted amino acids as neutral sphingomyelinase inhibitors
AU2001238424A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
AU2001243158A1 (en) 2000-02-18 2001-08-27 Merck And Co., Inc. Inhibitors of prenyl-protein transferase
DE10023484A1 (de) 2000-05-09 2001-11-22 Schering Ag Anthranylamide und deren Verwendung als Arzneimittel
EP1302201A4 (en) 2000-07-17 2007-09-05 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION WITH IMPROVED ABSORBABILITY
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US6576644B2 (en) 2000-09-06 2003-06-10 Bristol-Myers Squibb Co. Quinoline inhibitors of cGMP phosphodiesterase
AU2001294557A1 (en) 2000-09-11 2002-03-26 Merck And Co., Inc. Thrombin inhibitors
CA2428191A1 (en) 2000-11-07 2002-05-30 Bristol-Myers Squibb Company Acid derivatives useful as serine protease inhibitors
US7037528B2 (en) 2000-12-22 2006-05-02 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
RU2319701C2 (ru) 2001-02-21 2008-03-20 Астразенека Аб ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US7459470B2 (en) 2001-05-08 2008-12-02 Schering Ag N-oxide anthranylamide derivatives and their use as medicaments
OA12619A (en) 2001-06-21 2006-06-12 Pfizer Prod Inc Self-emulsifying formulations of cholesteryl estertransfer protein inhibitors.
MXPA03010165A (es) 2001-06-22 2004-03-10 Pfizer Prod Inc Composiciones farmaceuticas de adsorbatos de farmaco amorfo.
EP1269994A3 (en) 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
AU2002304387A1 (en) 2001-06-22 2003-01-08 Pfizer Products Inc. Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer
EP1401399A2 (en) 2001-06-22 2004-03-31 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
WO2003030909A1 (en) 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
US6713499B2 (en) 2001-12-12 2004-03-30 Hoffman-La Roche Inc. 7-Amino-benzothiazole derivatives
IL162870A0 (en) 2002-02-01 2005-11-20 Pfizer Prod Inc Controlled release pharmaceutical dosage forms of a cholesteryl estertransfer protein inhibitor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
GB0208280D0 (en) 2002-04-10 2002-05-22 Glaxo Group Ltd Novel compounds
US20040053842A1 (en) 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
DK1533292T3 (da) 2002-08-30 2007-06-04 Japan Tobacco Inc Dibenzylaminforbindelse og medicinsk anvendelse deraf
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
GB0303683D0 (en) 2003-02-18 2003-03-19 Prolysis Ltd Antimicrobial agents
MXPA05009102A (es) 2003-02-28 2006-05-31 Bayer Pharmaceuticals Corp Derivados de piridina sustituida utiles en el tratamiento del cancer y otros trastornos.
CN1859903A (zh) 2003-03-04 2006-11-08 辉瑞产品公司 Ep2选择性受体激动剂在药物治疗中的应用
ES2298782T3 (es) 2003-06-11 2008-05-16 Eli Lilly And Company 3-aminopirrolidinas como inhibidores de la reabsorcion de monoaminas.
RU2006102981A (ru) 2003-08-04 2007-09-20 Пфайзер Продактс Инк. (Us) Лекарственные формы, обеспечивающие контролируемое высвобождение ингибиторов белка-переносчика эфиров холестерина и немедленное высвобождение ингибиторов hmg-соа-редуктазы
WO2005021525A1 (en) 2003-08-27 2005-03-10 Janssen Pharmaceutica, N.V. Aryl piperidine amides
EP1670446A2 (en) 2003-09-26 2006-06-21 Japan Tobacco Inc. Method of inhibiting remnant lipoprotein production
PL1732933T3 (pl) 2004-03-26 2008-12-31 Lilly Co Eli Związki do leczenia dyslipidemii
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
WO2005100298A1 (en) 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
JP2008520645A (ja) 2004-11-23 2008-06-19 ファイザー・プロダクツ・インク ジベンジルアミン化合物および誘導体
US8604055B2 (en) * 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1848430B1 (en) * 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
WO2006129167A1 (en) 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
AU2006330072B2 (en) * 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
US8030359B2 (en) 2006-02-09 2011-10-04 Merck Sharp & Dohme Corp. Polymer formulations of CETP inhibitors
AU2007247385B2 (en) 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
US7790737B2 (en) * 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP4834699B2 (ja) * 2007-07-30 2011-12-14 田辺三菱製薬株式会社 医薬組成物
CN101418397A (zh) * 2008-12-02 2009-04-29 西北有色金属研究院 一种TiB2强化的MgAlB14超硬材料的制备方法

Also Published As

Publication number Publication date
US20140288072A1 (en) 2014-09-25
CN103958511A (zh) 2014-07-30
JP6140168B2 (ja) 2017-05-31
AU2012313971A8 (en) 2014-06-19
JP2014527997A (ja) 2014-10-23
HK1197238A1 (en) 2015-01-09
MX2014003660A (es) 2014-10-17
WO2013046045A1 (en) 2013-04-04
EP2760864B1 (en) 2018-01-24
AU2012313971B2 (en) 2016-09-29
CA2850022C (en) 2018-05-01
KR20140082689A (ko) 2014-07-02
CA2850022A1 (en) 2013-04-04
EP2760864A1 (en) 2014-08-06
IN2014CN02290A (es) 2015-06-19
AU2012313971A1 (en) 2014-05-01
US9000007B2 (en) 2015-04-07
KR101803866B1 (ko) 2017-12-04
NZ622698A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12015501452A1 (en) Novel quinolone derivatives
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
BR112014031068A2 (pt) derivados piridinona e piridazinona
IN2014CN03073A (es)
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
UA111770C2 (uk) Інгібітори бромдомену
IN2014DN09352A (es)
MX2014004479A (es) Derivados de oxazina novedosos y su uso en el tratamiento de enfermedades.
IN2014DN09348A (es)
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
BR112014001801A2 (pt) indazóis
EA201391098A1 (ru) C-28-амины c-3-модифицированных производных бетулиновой кислоты в качестве ингибиторов созревания вич
PH12014501283A1 (en) 4`-azido, 3``-fluoro substituted nucleoside derivatives as inhibitors of hcv rna replication
MX2015010354A (es) Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
EA201390984A1 (ru) Гетероциклические соединения, подходящие для лечения дислипидемии
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
IN2014DN09347A (es)
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
MX352074B (es) Derivados de 5-bencilaminometil-6-aminopirazolo [3,4-b] piridina como inhibidores de proteina de transferencia de ester de colesterilo (cetp) utiles para el tratamiento de aterosclerosis.
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
AU2012360910A8 (en) Quinazolinone derivatives as HCV inhibitors
MX357352B (es) Uso de derivados poliaminoisoprenilo en un tratamiento antibiotico o antiseptico.
BR112013027395A2 (pt) inibidores de 17alfa-hidroxilase/c17,20-liase
UA109804C2 (xx) 2-метоксипіридин-4-ільні похідні

Legal Events

Date Code Title Description
FG Grant or registration